Spain (ES)

Bioactive coatings on porous titanium for biomedical applications (2018) Dominguez-Trujillo C, Ternero F, Rodriguez-Ortiz JA, Heise S, Boccaccini AR, Lebrato J, Torres Y Journal article, Original article Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study (2018) Feagan BG, Panes J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, et al. Journal article Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients (2018) Rau M, Schmitt J, Berg T, Kremer A, Stieger B, Spanaus K, Bengsch B, et al. Journal article Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY (2018) Bossuyt P, Atreya R, Taxonera C, Hebuterne X, Isaacs K, Higgins PD, Lindsay J, et al. Conference contribution Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study (2018) Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Vidal Trueba H, et al. Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018) Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study (2018) Wolin EM, Pavel ME, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period (2018) Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Warner RRP, et al. Conference contribution Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients (2018) Fischer SM, Klenske E, Schmitt H, Vitali F, Hirschmann S, Koch F, Ramming A, et al. Conference contribution The polynucleotide kinase 3'-phosphatase gene (PNKP) is involved in Charcot-Marie-Tooth disease (CMT2B2) previously related to MED25 (2018) Leal A, Bogantes-Ledezma S, Ekici AB, Uebe S, Thiel C, Sticht H, Berghoff M, et al. Journal article